On 2 June 2026, Qyuns Therapeutics Co., Ltd. executed an on-exchange repurchase of 57,200 H-shares, according to the Next Day Disclosure Return filed with the Hong Kong Stock Exchange.

• Transaction details – Price range: HKD 15.96 to HKD 16.70 per share – Volume-weighted average price (Section I): HKD 16.51 per share – Aggregate consideration: HKD 0.94 million

• Impact on share capital – Outstanding issued shares (excluding treasury) fell from 224.19 million to 224.13 million, a reduction of 0.0255%. – Treasury share balance increased from 2.88 million to 2.94 million. – Total issued shares (including treasury) remained unchanged at 227.07 million.

• Repurchase mandate utilisation – Shareholders approved a mandate on 29 May 2026 authorising repurchases of up to 22.44 million shares. – Cumulative repurchases under the mandate now stand at 231,600 shares, representing 0.1032% of the company’s issued shares on the mandate date. – A 30-day moratorium on new share issues or treasury share sales runs until 2 July 2026.

The company confirmed that all repurchases were conducted in accordance with Main Board Rule 10.06 and that no material changes have been made to the explanatory statement dated 8 May 2026.